Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Efficacy

This publication has 32 references indexed in Scilit:

• Heart Disease and Stroke Statistics—2007 Update
  Circulation, 2007
• The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes
  Diabetes Care, 2007
• The Endocannabinoid System as a Target for the Treatment of Visceral Obesity and Metabolic Syndrome
  Annals of the New York Academy of Sciences, 2006
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy
  Pharmacological Reviews, 2006
• Prevalence of Overweight and Obesity in the United States, 1999-2004
  JAMA, 2006
• The role of the endocannabinoid system in the control of energy homeostasis
  International Journal of Obesity, 2006
• Cardiovascular Risk Management by Blocking the Endocannabinoid System
  Experimental and Clinical Endocrinology & Diabetes, 2006
• Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease
  Nature Clinical Practice Cardiovascular Medicine, 2006
• Adipokines: molecular links between obesity and atheroslcerosis
  American Journal of Physiology-Heart and Circulatory Physiology, 2005
• Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
  International Journal of Obesity, 2004